Recursion Pharmaceuticals, Inc. (RXRX) is a pioneering biotechnology company specializing in the various applications of artificial intelligence (AI) to discover new and effective drugs. The company’s unique approach seamlessly integrates Big Data, AI, and experimental biology as part of its innovative drug-discovery methodology.
The company was founded in 2013, and its primary focus is to revolutionize the entire process of drug discovery by expediting the conventional timeline. It is headquartered in Salt Lake City, Utah, USA.
Recursion seeks to model biological processes down to the mechanistic cellular level, which helps it understand how diseases manifest and progress. The company uses AI-guided robotics to create disease-induced cellular models of human disease, then applies its proprietary AI analytical platform to data from these models to identify potential therapeutics.
Recursion’s AI platform has the ability to process over 1 Petabyte (equivalent to 1 million gigabytes) of data weekly, which helps the company scrutinize countless possible molecular configurations that may be therapeutically beneficial. Then, these potential drug candidates are tested in lab environments. As a result, Recursion has been able to identify several drugs for treating multiple conditions, ranging from common conditions like inflammation to rare genetic disorders.
One of the ways Recursion has differentiated itself is by making its computational biology platform accessible to others. The company's RXRX1 dataset, which is one of the largest public biological image datasets in the world, is open for other researchers and scientists to use. It is a pioneering step towards collaborative drug discovery which could exponentially speed up the process of finding cures for diseases.
Recursion has also formed strategic partnerships with big pharmaceutical firms, including Takeda Pharmaceutical, to co-develop drugs and therapies for a range of illnesses, including rare genetic diseases, inflammation, immuno-oncology, and more. This indicates that Recursion's approach has won validation from some of the biggest players in the pharmaceutical industry.
Recursion Pharmaceuticals, Inc. is helmed by a team of ambitious and experienced professionals, driven by a common goal – to decode biology and radically improve lives. The company’s vision extends well beyond the traditional drug discovery path, and its novel approach could usher in a new era of therapeutics that are developed much more efficiently, cheaply, and rapidly. The company is traded on the NASDAQ under the ticker RXRX.